Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...

Long before the genome was mapped, before investors went Internet crazy, even before color television, David and Alice Schwartz started a scientific supply company called Bio-Rad Laboratories. Now, 50 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Moby Strategic Performance Drivers and Operational Context. Management attributed the Q4 gross margin miss to execution- ...